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Accepted 7 September 2010AbstractOvarian hyperstimulation syndrome (OHSS) is a relatively common complication of ovarian stimulation and can be life threatening. The
pathophysiology of OHSS is characterized by increased capillary permeability, leading to leakage of fluid from the vascular compartment, with
third-space fluid accumulation and intravascular dehydration. The increased intra-abdominal pressure indicated that OHSS may be considered
a compartment syndrome. Vascular endothelial growth factor, also known as vascular permeability factor, has emerged as one of the mediators
intrinsic to the development of OHSS. Conventional management is focused on supportive care until the spontaneous resolution of the condition.
The standard of care for treatmentdmonitoring of appropriate clinical parameters, fluid balance management, thrombosis prophylaxis, and
ascites treatmentdshould prevent severe morbidity in most cases. This review will cover inpatient and outpatient management. The potential
therapeutic approach targeting the vascular endothelial growth factor system will be discussed.
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Ovarian hyperstimulation syndrome (OHSS) is a relatively
common complication of ovarian stimulation and can be life
threatening [1]. In severe cases, a critical condition develops
with massive ascites, marked ovarian enlargement, pleural
effusion, electrolyte imbalance, and hypovolemia with hypo-
tension and oliguria [2].
Unlike tumor angiogenesis, OHSS is self-limiting and will
undergo gradual resolution with time. Conventional manage-
ment is focused on supportive care until the spontaneous
resolution of the condition. This review will explore the path-
ophysiology of OHSS and its management. The potential
therapeutic approach targeting the vascular endothelial growth
factor (VEGF) system will be discussed. Improved under-
standing of the pathogenesis of OHSS should facilitate more* Corresponding author. Department of Obstetrics and Gynecology, National
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and minimize the occurrence of OHSS [3].Pathophysiology
The pathophysiology of OHSS is characterized by increased
capillary permeability, leading to leakage of fluid from the
vascular compartment, with third-space fluid accumulation and
intravascular dehydration [4]. The cause of OHSS is unknown,
but it may be mediated by vasoactive cytokines secreted in
excess by hyperstimulated ovaries [5], and it is believed that
these ovarian factors are secreted by corpora lutea in response to
human chorionic gonadotropin (hCG) stimulation [6e8].
Proinflammatory cytokines [interleukin-1b (IL-1b), IL-6,
IL-8, and tumor necrosis factor-a] have been implicated as
mediators of the acute-phase response [9], which is character-
ized by capillary leakage similar to that seen in OHSS. VEGF,
also known as vascular permeability factor, has emerged as one
of the factors most likely involved in the pathophysiology of
OHSS [10]. VEGF is an angiogenic cytokine, which is a potentcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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integral role in follicular growth, corpus luteum function, and
ovarian angiogenesis. In human, hCG administration increased
VEGF expression in granulose-lutein cells [11]. High serum,
peritoneal fluid, and follicular fluid VEGF, IL-6, and IL-8
concentrations have been correlated with the development of
OHSS and its severity [7,12e15]. Hence, the inhibition of
vascular permeability appears to be an attractive and novel
therapeutic approach to preventing and treating OHSS (Fig. 1).Hemodynamic changes of OHSSThe clinical manifestations originate from the combination
of decreased intravascular space and the accumulation of
protein-rich fluid into body cavities and interstitial space. This
“third spacing” causes depletion of the intravascular space. Loss
of intravascular volume leads to hemodynamic changes man-
ifested as hypotension, severe tachycardia, and decreased renal
perfusion as well as hemoconcentration. Hemoconcentration
with increase in blood coagulability is responsible for arterial
and venous thrombotic phenomena in patients with OHSS [16].
Loss of intravascular volume combined with decreased renal
perfusion results in electrolyte abnormalities (hyperkalemia,
hyponatremia), increase in hematocrit and white cell count, and
decrease in creatinine clearance.
The most common symptom of OHSS (abdominal discom-
fort) is because of the development of ascites. Accumulation of
protein-rich fluid in the peritoneal cavity leads to abdominal
distention and increased intra-abdominal pressure (IAP).Fig. 1. Pathophysiology of ovarian hyperstimulation syndrome. hCG ¼ human
chorionic gonadotropin; IL-6 ¼ interleukin-6; IL-8 ¼ interleukin-8; VEGF ¼
vascular endothelial growth factor.Increased IAP has deleterious effects on end-organ function and
may compromise respiratory, cardiovascular, renal, gastroin-
testinal, and hepatic system homeostasis [17,18]. An under-
standing of the pathophysiology of increased IAP is useful in
the management of OHSS.
Changes in IAP have a great impact on renal function and
urine production. One of the first visible signs of intra-
abdominal hypertension (IAH) is oliguria, which occurs at an
IAP of 15e20 mmHg [19]. Renal dysfunction secondary to
increased IAP results from the decrease in cardiac output, direct
compression of renal vessels and parenchyma with decreased
renal blood flow, increased renal vascular resistance, and
redistribution of renal blood flow from the cortex to themedulla.
Experimental studies demonstrated that IAP >15e20 mmHg
was associated with decreased glomerular filtration rate and
oliguria, which progressed to anuria when IAP values exceeded
30mmHg [20]. The same is true for all the intra-abdominal low-
pressure vessels that supply the intestines. Initial venous
compression results in parenchyma edema. Intestinal edema is
responsible for the nausea and the diarrhea, which often occurs
in patients with OHSS.
Increased IAP leads to decreased splanchnic and hepatic
perfusion with tissular hypoxia. Animal studies showed
a significant impairment of hepatic artery and portal vein blood
flow at IAP of 10mmHg and decreasedmesenteric blood flow at
IAP of 20 mmHg [17]. Liver edema is manifested with an
increase in liver function tests [15]. The increase in IAP leads to
elevation of the diaphragm with increased intrathoracic and
pleural pressures, resulting in progressive reduction in lung and
chest wall compliance. Pulmonary function may be compro-
mised in cases of severe OHSS by several mechanisms that act
synergistically: elevation of the diaphragm, accumulation of
fluid in the pleura, and interstitial edema [21]. Although pleural
effusion is generally thought to be a consequence of pronounced
ascites, associated with a shift of liquid from the peritoneal
cavity to the pleura, isolated pleural effusion without concom-
itant ascites has been reported as the only symptom of OHSS
[22e24]. The pathogenesis of isolated hydrothorax in cases of
OHSS remains unclear.OHSS may be considered as an abdominal compartment
syndromeThe increased IAP indicates that OHSS may be considered
a compartment syndrome. IAH is defined by a sustained or
repeated pathologic elevation of IAP 12 mmHg. Abdominal
compartment syndrome (ACS) is defined as a sustained IAP
>20mmHg that is associatedwith new organ dysfunction/failure
[25,26]. Primary ACS is a condition associated with injury or
disease in the abdominopelvic region. Secondary ACS refers to
conditions that do not originate from the abdominopelvic region,
such as sepsis and capillary leak syndrome, major burns, and
other conditions requiring massive fluid resuscitation, yet
resulting in the signs and symptoms commonly associated with
the ACS [25].
The most important factor responsible for the development
of ACS might be excessive fluid administration, which can
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ability. The hemodynamic changes associated with moderate
to severe OHSS strongly resemble those of an ACS [27].
Increased IAP has been documented for 20 OHSS patients in
the literature [28,29], with increased IAP reported in moderate
and severe OHSS cases. Cil et al [28] documented an IAP of
54 cm H2O by bladder catheter, equivalent to 40 mmHg, which
satisfies criteria for ACS. Another study found mean IAP of
17.5  1.24 cm H2O, equal to 12.9  0.91 mmHg, in 19 OHSS
patients with varying symptoms including decline in respiratory
function, tense ascites, oliguria, or a combination of these [29].
It should be noted that a rapid increase in IAP may affect
symptoms and signs. Based on these observations, and the well-
established link between IAH and organ dysfunction, it is
logical to consider how IAP measurement may correlate with
the disease severity in OHSS patients [27].
Classification of OHSS
Conventional OHSS staging has relied on clinical symptoms
and laboratory findings to categorize severity of disease. The
most popular classification system for staging OHSS is that of
Golan et al [30]. This system incorporated the use of trans-
vaginal sonography for both estimating of ovarian enlargement
and detection of ascitic fluid. The detection of ascites estab-
lishes the diagnosis of moderate OHSS. Subsequent modifica-
tions defined a group of critical or complicated OHSS and added
to the severe category of the syndrome [31,32].
It should be remembered that OHSS is a dynamic situation.
The clinical symptoms and signs of OHSS exhibit a continuum
of scope and severity that defies attempts at specific classifi-
cation. A moderate OHSS patient may progress within hours
or days to a severe case. Therefore, clinicians cannot be
overcautious in patient monitoring of moderate or even mild
OHSS. Management of patients with OHSS should be there-
fore based on the severity of the syndrome according to
a simple, but comprehensive classification.
In 2003, the Practice Committee of the American Society for
Reproductive Medicine proposed a simplified classification of
the syndrome into mild, worsening, and serious [33,34]. It also
defined criteria for outpatient or inpatient management.
Progression of illness is recognized when symptoms persist,
worsen, or include ascites that may be demonstrated by in-
creasing abdominal girth or ultrasound evaluation. Serious
illness was defined by the presence of abdominal pain plus one
or more of the following signs: rapid weight gain, tense ascites,
hemodynamic instability, respiratory distress, progressive oli-
guria, and laboratory abnormalities. Laboratory criteria for
women with serious illness include: hemoconcentration
(hematocrit >45%), leukocytosis (white blood cell count
>15,000), sodium less than 135mEq/L, potassiumofmore than
5.0 mEq/L, elevated liver enzymes, and serum creatinine of
more than 1.2 mg/dL. According to the Practice Committee,
most patients with serious illness require hospitalization.
A division of OHSS into “early” and “late”, depending on
the time of onset, may be useful in determining the prognosis
[35,36]. OHSS presenting within 9 days after the ovulatorydose of hCG is likely to reflect excessive ovarian response and
the precipitating effect of exogenous hCG administered for
final follicular maturation. OHSS presenting after this period
reflects endogenous hCG stimulation from an early pregnancy
[35]. Late OHSS is more likely to be severe and to last longer
than early OHSS.
Advanced stages of OHSS share a hemodynamic patho-
physiology with ACS. Measurement of IAP may help to
classify the stage of OHSS [27]. The potential importance of
IAP in classification of the severity of OHSS requires further
studies.
Management
The best treatment in OHSS is prevention. However, there are
no precise methods to completely prevent severe OHSS [37,38].
Conventional management of OHSS is focused on supportive
care until the spontaneous resolution of the condition. The
standard of care for treatment [39]dmonitoring of appropriate
clinical parameters, fluid balance management, thrombosis
prophylaxis, and ascites treatmentdshould prevent severe
morbidity in most cases.
An understanding of the pathophysiology of increased IAP
and OHSS is useful in the management of OHSS. Nonoperative
management strategies are now recognized as playing a vital
role in both the prevention and treatment of organ dysfunction
and failure because of elevated IAP [40]. The nonoperative
management of IAH/ACS can be summarized using five ther-
apeutic goals: (1) evacuate intraluminal contents; (2) evacuate
intra-abdominal space-occupying lesions (e.g. ascites); (3)
improve abdominal wall compliance; (4) optimize fluid
administration; and (5) optimize systemic and regional tissue
perfusion [41]. These fundamental management concepts
remain appropriate for OHSS patients with elevated IAP.
The present section will cover outpatient and inpatient
management. The potential therapeutic approach targeting the
VEGF system will be discussed.Outpatient managementPatients with mild manifestation of OHSS do not require any
specific treatment. Outpatient surveillance is, nevertheless,
mandatory to detect cases that may progress to moderate or
severe OHSS. Most patients with moderate OHSS still can be
managed on an outpatient basis, but they require more careful
evaluation including daily weight and abdominal girth
measurement, physical and ultrasound examination to detect
increasing ascites, and to measure ovarian size. Oral fluid intake
should be maintained at no less than 1 L per day.Women should
be encouraged to drink to thirst, rather than to excess. Strenuous
exercise and sexual intercourse should be avoided. Strict bed
rest is unwarranted and may increase risk of thromboembolism.
Discomfort may be relieved with acetaminophen or opiate
medications if severe. Nonsteroidal anti-inflammatory agents
are not recommended because they may compromise renal
function in patients with OHSS [42]. If symptoms are wors-
ening, weight continues to increase at 1 kg/day or more, or urine
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brought back to the office for physical examination, ultrasound,
and laboratory evaluation include hematocrit, electrolytes, and
serum creatinine. The patient should be aware that her condition
may worsen if pregnancy ensues.
An alternative strategy for treatment of OHSS consists of
early intervention with paracentesis in an outpatient setting. In
1994, Shrivastav et al [43] reported a comparison of inpatient
versus outpatient management of severe OHSS and concluded
that outpatient management was a safe and effective treatment
alternative. The efficacy of outpatient treatment has been
confirmed in subsequent studies [44e46] and has recently been
shown to be cost effective [47]. In aggressively treating OHSS
with paracentesis before the development of symptoms
including weight gain, hemoconcentration, electrolyte imbal-
ance, or renal abnormality, only 9.4% of patients ultimately
required hospitalization for repetitive culdocenteses [44].
Smith et al [45] reported 25 of 29 (86%) patients with severe
OHSS were managed as outpatients with transvaginal para-
centesis with no complication. They have demonstrated that
outpatient transvaginal paracentesis may be used safely in the
management of patients with even severe OHSS. Therefore,
there has been a trend toward the use of outpatient management
with paracentesis for moderate to severe OHSS. Early inter-
vention to avoid progression, rather than waiting passively,
remains an attractive approach that deserves prospective
evaluation.Hospitalization managementWomen with serious illness or severe OHSS require hospi-
talization for more careful monitoring and aggressive treatment.
Careful and frequent reevaluation of the hospitalized patient
with severe OHSS is essential. Clinical examination includes an
assessment of hydration and cardiorespiratory system.
Abdominal circumference and weight should be recorded at
admission and daily until resolution. Fluid intake and output
should be recorded andmonitored on at least a daily basis. Urine
output of less than 1,000 mL/day is a matter of concern.
Biochemical monitoring should include serum electrolytes,
renal and liver function tests, a coagulation profile, and blood
count. Sonographic examination provides assessment of
ovarian size and the presence of ascites as well as pleural, or
pericardial effusions. A chest X-ray and pulse oximetry are
mandatory for any patient with respiratory symptoms and signs
suggestive of hydrothorax, pulmonary infection, or pulmonary
embolism. Assay of b-hCG will help to diagnose pregnancy as
early as possible.
Pain and ascites can easily mask adnexal torsion, ovarian
rupture, and acute intra-abdominal hemorrhage. Serial clinical
and laboratory evaluations provide the means to monitor
progression of illness and to recognize evidence of resolution.Optimize fluid administrationFig. 2. Fluid management of ovarian hyperstimulation syndrome. Hct ¼
hematocrit.The management of OHSS is essentially supportive, aiming
at refilling the arteriolar bed, maintaining circulatoryhemodynamics, and preventing hemoconcentration [39]. It is
well known that hypovolemia potentiates the pathophysiologic
effects of elevated IAP and predisposes patients to developing
multiple system organ failure [17]. Maintenance of adequate
intravascular volume must always remain the first priority to
ensure appropriate tissue and organ perfusion and avoid the
development of multisystem organ failure. Hospitalized
patients require intravenous (IV) fluid management to address
the acute need for volume expansion while also considering the
marked increase in vascular permeability. Correction of hypo-
volemia, hypotension, and oliguria has highest priority,
accepting that fluid administration may contribute to the accu-
mulation of ascites.
Rapid initial hydrationmay be accomplishedwith bolus of IV
fluid (1,000mL normal saline) tomaintain adequate urine output
and reverse hemoconcentration [39]. If urine output response is
adequate and hematocrit normalizes, switch to dextrose 5%
normal saline and maintain at the rate of 125e150 mL/hr while
monitoring very closely every 4 hours. If urine output is inade-
quate in response to fluid bolus and the hematocrit does not
reflect a change toward euvolumia, IV crystalloid fluids may be
stopped and albumin (25%) in doses of 50 g, infusedmore than 4
hours, and repeated at 4- to 12-hour intervals as necessary, is an
effective plasma expander [34] (Fig. 2).
Diuretic therapy is usually contraindicated in patients with
hemoconcentration as these patients are intravascularly volume
depleted secondary to capillary leak. After the patient is
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has resolved (hematocrit <38%), however, diuretics (e.g.
furosemide, 20 mg IV) in combination with colloids may be
considered to mobilize the third-space edema.
As soon as the intravascular volume and electrolyte
changes have been corrected, and the patient has adequate
urine output and onset of a brisk diuresis, she can be switched
to oral intake. After the patient can tolerate oral intake and has
adequate urine output she could be discharged at home.The use of hypertonic crystalloidsHypertonic saline has been in clinical use for many decades.
The range of concentrations used clinically varies from 1.8% to
30% saline. Its osmotic and volume-expanding properties make
it theoretically useful for a number of indications. In addition to
the ability of hypertonic solutions to withdraw intracellular
water to increase plasma volume, hypertonic saline may
decrease microvascular fluid loss during states of elevated
microvascular leak [48].
The mechanism of action of hypertonic saline is predomi-
nantly through the marked osmotic shift of fluid from the
intracellular to the interstitial and intravascular space [49].
Endothelial cell volume increases as a result of water accumu-
lation. An important effect of hypertonic saline-induced osmotic
fluid shift is the normalization of endothelial cell volume.
Hypertonic saline has been shown to be anticoagulant in vitro
when 5e10% of blood has been replaced with 7.5% hypertonic
saline [50]. This equates to an approximate dose of 3.5e7 mL/
kg of 7.5% hypertonic saline. No significant side effects were
reported. The anticoagulant properties make it beneficial for
OHSS patients who are at particular risk of thromboembolism.
In severe OHSS, patients always present electrolyte imbal-
ance (hyponatremia, hyperkalemia) at the time of hospitaliza-
tion. Hyponatremia may be dilutional as a result of antidiuretic
hormone hypersecretion. Ayus et al [51], in a prospective study
of 33 patients, successfully and safely treated symptomatic
hyponatremia with a prolonged infusion (average of 17 hours)
of 5% hypertonic saline. One to two milliliters per kilogram per
hour of 3% hypertonic saline has been suggested to raise the
serum sodium by 1e2 mmol/hr. A consensus statement in 2005
suggested that 3% hypertonic saline be used for symptomatic
patients, either as a 100 mL of rapid infusion followed by
100 mL/hr, or at a rate of 1e2 mL/kg/hr [52]. Safety concerns
with the use of hypertonic saline center mostly on the conse-
quences of an acute hyperosmolar state. Further potential side
effects include hyperchloremic acidosis and hyperosmolar renal
failure [53]. There are far fewer studies using continuous
infusions of hypertonic saline.
Current evidences suggest that hypertonic saline solutions,
either alone or in combination with colloid solutions, can be
used with good effect in certain circumstances [49,54]. The
use of hypertonic saline has been demonstrated to result in
significant reductions in IAP, decreased fluid requirements,
and decreased risk of subsequent secondary ACS [54]. The use
of hypertonic and/or colloid resuscitation fluids should there-
fore be strongly considered in any patient with elevated IAP[40]. However, it is unclear what the ideal concentration,
formulation, or volume of hypertonic saline is. Future studies
will hopefully elucidate the precise risk benefit ratio for the
use of hypertonic saline solutions in OHSS patients, and define
the most appropriate mode and means of administration as
well as the optimal mode of monitoring for adverse effects.ParacentesisThe presence of ascites is the hallmark of OHSS. In fact,
symptoms resulting from ascites are often the most common
reason for hospitalization. One goal of OHSS management is
to prevent progression in disease severity. However, aspiration
of ascitic fluid (paracentesis) is not indicated in every patient
with OHSS. Current indications for paracentesis are based on
symptomatic complaints of dyspnea, abdominal distension and
pain, or oliguria. Navot et al [31] suggested that paracentesis is
the single most important treatment modality in life-threat-
ening OHSS not controlled by medical therapy.
Immediately after paracentesis, characteristic hemodynamic
changes occur including decreased IAP, improved venous
return, and improved renal and uterine perfusion [55]. Removal
of ascites up to 7.5 L on one occasion and 45 L in total by serial
vaginal paracentesis may be safe in patients with severe OHSS
[56]. In patients with cirrhosis, the maximal hemodynamic
effect was demonstrated after removal of >750 mL of ascites
fluid [57]. Our experience showed that a marked relief of
compression symptoms occurred after removing the first
1,000 mL of ascitic fluid [55]. However, incomplete tapping
might result in rapid recollection of ascites, requiring retapping.
Serial IAP measurements may prove to be helpful in
monitoring severe cases of OHSS. Based on existing literature
for the management of IAH and ACS, an IAP >20 mmHg
warrants decompression [25], which in OHSS patients is
accomplished by paracentesis. If OHSS is considered to be
a compartment syndrome, then early intervention with para-
centesis even for moderate cases where ascites is found would
seem the most logical plan of care [27].
Outpatient management with vaginal paracentesis at early
stages of OHSS has been proposed as a safe and effective
modality of treatment [43e45,47]. However, such management
protocols often include multiple visits and drainage procedures
with increased cost and inconvenience. Although severe OHSS
can be managed on an outpatient basis, many physicians still
recommend hospitalization of patients presenting with this
condition [34,39]. Patients who fail to tolerate oral fluids, are
dehydrated or require supportive care, such as pain control,
should be hospitalized.
Repeat paracentesis may be indicated for fluid reac-
cumulation in patients with moderate or severe disease who
again become symptomatic [55]. The placement of a catheter
instead of multiple needle paracentesis would permit complete
drainage through one, rather than several, interventions.
Several reports have described the use of an indwelling
transabdominal pigtail catheter placement for continuous
drainage of ascites in patients with OHSS [58,59]. Percuta-
neous placement of a pigtail catheter has been demonstrated as
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ascites in severe OHSS [59]. It may represent an attractive
alternative to multiple paracentesis.ThromboprophylaxisThere are no firm data indicating either the value of diag-
nostic tests or heparin prophylaxis to prevent thromboembolic
complications during controlled ovarian stimulation and in
patients who develop OHSS [16]. However, as thromboem-
bolism is a potentially life-threatening complication, throm-
boprophylaxis should be considered for patients who develop
moderate to severe OHSS. Low-molecular weight heparin
(LMWH) should ameliorate the risk of thrombotic compli-
cations, and thromboprophylaxis using pregnancy-related
LMWH doses (e.g. 40 mg enoxaparin or 5,000 IU dalteparin
daily) is now part of many recommended treatment protocols
[60]. LMWH has been favored over unfractionated heparin
because of ease of administration and lack of monitoring
needed. In women who do not conceive, thromboprophylaxis
may be discontinued with resolution of OHSS. For women
who do conceive, continuation until the end of the first
trimester, or even longer, depending on the presence of
additional risk factors and course of the OHSS.
OHSS can be more unpredictable in severity and course in
women who are pregnant. Clinically, progression of throm-
boembolism is seen in approximately 10% of cases suggests
that adequate anticoagulation must be implemented promptly
[60]. Pregnant women with OHSS and thromboembolic
complications face a treatment dilemma. Successful manage-
ment has been reported in a pregnant woman with OHSS and
superior sagittal sinus thrombosis, and continuation of preg-
nancy has been considered safe [61]. The appropriate duration
of therapy for thromboembolism in this situation is not yet
established, although idiopathic venous thromboembolism is
generally treated for 6 months. If, however, an early pregnancy
has been diagnosed in the patient with critical complications of
OHSS, the pregnancy may need to be terminated to prevent
further deterioration of her condition.
Novel medical treatmentsDopamine and dopamine agonistDopamine has been used in oliguric patients with severe
OHSS, resulting in significant improvement in renal function
[62,63]. Dopamine produces its renal effect by increasing
renal blood flow and glomerular filtration. This is accom-
plished by means of stimulation of the dopaminergic recep-
tors present in the vascular kidney. Ferraretti et al [62]
reported on the successful treatment of seven patients with
severe OHSS using low doses of dopamine (4.32 mg/kg body
weight/24 h) by peripheral infusion. Tsunoda et al [63]
reported on 27 hospitalized patients, because of OHSS and
refractory to the initial therapy with IV albumin, were treated
by docarpamine (an oral dopamine prodrug). In 19 (86.4%) of
22 patients treated, clinical symptoms associated with asciteswere gradually improved after administrating docarpamine.
Oral docarpamine administration could be one of the options
in the management of patients with OHSS using dopamine
therapy. However, dopamine receptor 2 (DR-2) agonist,
cabergoline, seems to be more effective and tolerated than
dopamine.
It was recently found that dopamine or DR-2 agonists inhibit
vascular endothelial growth factor receptor 2-dependent
vascular permeability and angiogenesis through DR-2 of
endothelial cells [64]. In a rat OHSSmodel [65], administration
of a dopamine agonist, cabergoline, inactivates vascular endo-
thelial growth factor receptor 2 and prevents the increase in
vascular permeability. Alvarez et al [66] conducted a pilot study
on patients at risk of developing OHSS who were given
cabergoline (0.5 mg/day) orally from the day of hCG for 9 days.
They observed that ascites, hemoconcentration, vascular
hyperpermeability, and OHSS were significantly reduced. They
further demonstrated that implantation and pregnancy outcome
were not affected by cabergoline treatment [67]. Another
prospective randomized study [68] also showed that cabergo-
line reduces the early onset of OHSS with no changes in
pregnancy, implantation, or miscarriages rates. Recently,
a systematic review and meta-analysis of four randomized trials
comparing the prophylactic effect of the dopamine agonist,
cabergoline, versus no treatment in IVF cycles showed that
prophylactic treatment with cabergoline reduces the incidence,
but not the severity of OHSS, without compromising pregnancy
outcomes [69].
Cabergoline, however, has been associated with valvular
heart disease when administered chronically in patients with
Parkinson’s disease [70]. Quinagolide is a nonergot-derived DR-
2 receptor agonist. The use of quinagolide does not seem to be
associated with an increased prevalence of heart complications
[71]. Dopamine agonists are also differentiated by their phar-
macokinetic profile, as indicated by a much shorter half-life of
quinagolide (w17 hours) compared with cabergoline (w63e69
hours), thus minimizing exposure during organogenesis when
used in an IVF setting. These two features make quinagolide an
interesting dopamine agonist for use in prevention of OHSS. A
randomized, double-blind, multicentre study [72] suggests that
quinagolide at a dose of 200 mg/day reduces the frequency of
moderate/severe early OHSS without compromising pregnancy
or treatment outcome. The findings from this study may be
especially relevant for oocyte donation programs and for patients
with postponed embryo transfer.
One may concern that starting cabergoline after disease
manifestation would not provide sufficient time to stop rapidly
deteriorating clinical conditions in OHSS patients. The use of
gonadotropin-releasing hormone (GnRH) antagonists has been
associated with a significantly lower risk of OHSS compared
with GnRH agonist [73]. The mechanism of action of the
lower risk of OHSS has not been definitely determined, but
GnRH antagonist is reported to have a prominent luteolytic
effect [74]. Lainas et al [75] reported on successful manage-
ment of severe early OHSS by reinitiating GnRH antagonist 3
days after oocyte retrieval in combination with embryo cryo-
preservation. Rollene et al [76] described an outpatient
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zation of symptoms with minimal side effect. Four consecutive
patients of early onset OHSS were prescribed 0.5 mg of
cabergoline by mouth daily for 7 days and 250 g of ganirex
subcutaneous to be repeated once in 24 hours and all embryos
were frozen. No side effects were reported and no patients
required hospitalization. They concluded that dopamine
agonists and GnRH antagonists, when given together at the
time of diagnosis of OHSS, appear to work rapidly and
effectively to diminish the clinical symptoms of the disease
[76]. The potential benefit of finding an outpatient treatment of
OHSS with rapid onset and minimal side effects warrants
further investigation into this protocol.DoxycyclineDoxycycline, a tetracycline derivative, has been shown to
inhibit angiogenesis in human model [77]. Fainaru et al [78]
have demonstrated that oral doxycycline prevents VEGF-
induced vascular permeability, IL-2-induced pulmonary edema,
delayed-type hypersensitivity reactions, and tumor vessel
hyperpermeability in mice. They recently reported that doxy-
cycline directly inhibits vascular hyperpermeability in a mouse
model of OHSS in a dose-dependent manner [79]. Doxycycline
decreased the gonadotropin-induced general edema formation,
the development of ascites, and the direct permeability of
peritoneal blood vessels. Importantly, doxycycline did not
affect angiogenesis in the corpus luteum, but rather the vascular
hyperpermeability effect caused by the gonadotropin-induced
proangiogenic milieu [79]. Doxycycline’s potential in pre-
venting/treating human OHSS warrants further studies.
Conclusions
OHSS represents one of the most important complications
of ovarian stimulation. The syndrome should be respected for
its potential to cause critical morbidity or even death. Expe-
rience with ovulation induction therapy and knowledge OHSS
pathophysiology and clinical features are key to preventing
and managing OHSS.
Conventional management is focused on supportive care
until the spontaneous resolution of the condition. If OHSS is
considered to be a compartment syndrome, then early inter-
vention with paracentesis would seem the most logical plan of
care. Recently, there has been a trend toward the use of
outpatient management with early paracentesis for moderate
to severe OHSS.
VEGF has emerged as one of the mediators intrinsic to the
development of OHSS. The inhibition of vascular permeability
appears to be an attractive and novel therapeutic approach to
preventing and treating OHSS. Antiangiogenesis agents, such
as VEGF antagonists or doxycycline, could offer theoretical
advantages, but are still remote from clinical applications.
Recently, DR-2 agonists have been shown to counteract
VEGF-induced vascular permeability. The lack of toxic or
teratogenic effects could make cabergoline or quinagolide an
effective and safe etiological approach for OHSS prevention/treatment. Further studies are needed to establish protocols for
OHSS prevention and treatment using these compounds.
References
[1] Madill JJ, Mullen NB, Harrison BP. Ovarian hyperstimulation syndrome:
a potentially fatal complication of early pregnancy. J Emerg Med 2008;
35:283e6.
[2] Chen CD, Wu MY, Chao KH, Chen SU, Ho HN, Yang YS. Serum
estradiol level and oocyte number in predicting severe ovarian hyper-
stimulation syndrome. J Formos Med Assoc 1997;96:829e34.
[3] Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian
hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010;
94:389e400.
[4] Polishuk WZ, Schenker JG. Ovarian overstimulation syndrome. Fertil
Steril 1969;20:443e50.
[5] Goldsman MP, Pedram A, Dominguez CE, Ciuffardi I, Levin E,
Asch RH. Increased capillary permeability induced by human follicular
fluid: a hypothesis for an ovarian origin of the hyperstimulation
syndrome. Fertil Steril 1995;63:268e72.
[6] Chen SU, Chen CD, Yang YS. Ovarian hyperstimulation syndrome
(OHSS): new strategies of prevention and treatment. J Formos Med
Assoc 2008;107:509e12.
[7] Chen SU, Chou CH, Lee H, Ho CH, Lin CW, Yang YS. Lysophos-
phatidic acid up-regulates expression of interleukin-8 and -6 in gran-
ulosa-lutein cells through its receptors and nuclear factor-kB
dependent pathways: implications for angiogenesis of corpus luteum
and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab
2008;93:935e43.
[8] Chen SU, Chen RJ, Shieh JY, Chou CH, Lin CW, Lu HF, et al. Human
chorionic gonadotropin up-regulates expression of myeloid cell
leukemia-1 protein in human granulosa-lutein cells: implication of
corpus luteum rescue and ovarian hyperstimulation syndrome. J Clin
Endocrinol Metab 2010;95:3982e92.
[9] Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the
treatment of the systemic inflammatory response syndrome. JAMA 1993;
269:1829e35.
[10] McClure N, Healy DL, Rogers PAW, Sullivan J, Beaton L, Haning Jr RV,
et al. Vascular endothelial growth factor as capillary permeability agent
in ovarian hyperstimulation syndrome. Lancet 1994;344:235e6.
[11] Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, et al.
Human chorionic gonadotropin-induced ovarian hyperstimulation
syndrome is associated with up-regulation of vascular endothelial growth
factor. J Clin Endocrinol Metab 2002;87:3300e8.
[12] Chen CD, Chen HF, Lu HF, Chen SU, Ho HN, Yang YS. Value of serum
and follicular fluid cytokine profile in the prediction of moderate to
severe ovarian hyperstimulation syndrome. Hum Reprod 2000;15:
1037e42.
[13] Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Prognostic
importance of serial cytokine changes in ascites and pleural effusion in
women with severe ovarian hyperstimulation syndrome. Fertil Steril
1999;72:286e92.
[14] Chen SU, Chou CH, Lin CW, Lee H, Wu JC, Lu HF, et al. Signal
mechanisms of vascular endothelial growth factor and interleukin-8 in
ovarian hyperstimulation syndrome: dopamine targets their common
pathways. Hum Reprod 2010;25:757e67.
[15] Chen CD, Wu MY, Chen HF, Chen SU, Ho HN, Yang YS. Relationships
of serum pro-inflammatory cytokines and vascular endothelial growth
factor with liver dysfunction in severe ovarian hyperstimulation
syndrome. Hum Reprod 2000;15:66e71.
[16] Chan WS. The ‘ART’ of thrombosis: a review of arterial and venous
thrombosis in assisted reproductive technology. Curr Opin Obstet
Gynecol 2009;21:207e18.
[17] Carlotti AP, Carvalho WB. Abdominal compartment syndrome: a review.
Pediatr Crit Care Med 2009;10:115e20.
[18] Selgas R, Del Peso G, Bajo MA. Intra-abdominal hypertension favors
ascites. Perit Dial Int 2010;30:156e7.
9C.-D. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 2e10[19] Cheatham ML. Abdominal compartment syndrome: pathophysiology and
definitions. Scand J Trauma Resusc Emerg Med 2009;17:10.
[20] Harman PK, Kron IL, McLachlanHD, Freedlender AE, Nolan SP. Elevated
intra-abdominal pressure and renal function. Ann Surg 1982;196:594e7.
[21] Vlahos NF, Gregoriou O. Prevention and management of ovarian
hyperstimulation syndrome. Ann N Y Acad Sci 2006;1092:247e64.
[22] Hsieh MJ, Tsao TC, Cheng PJ. Ovarian hyperstimulation syndrome with
minimal ascites and massive pleural effusion: report of a case. J Formos
Med Assoc 1994;93:882e4.
[23] Tang HH, Tsai YC, Kang CY, Chung MT, Loo TC, Huang KF. Atypical
ovarian hyperstimulation syndrome with isolated pleural effusion but
without ascites or hemoconcentration. Taiwan J Obstet Gynecol 2007;46:
180e2.
[24] Beji O, Brahmi N, Thabet H, Mokline A, Abidi N, Blel Y, et al.
Compressive pleural effusion after ovarian hyperstimulation syn-
dromeda case report and review. Fertil Steril 2008;89:1826.e1e3.
[25] Malbrain M, Cheatham M, Kirkpatrick A, Sugrue M, Parr M, De
Waele J, et al. Results from the international conference of experts on
intra-abdominal hypertension and abdominal compartment syndrome. I.
Definitions. Intensive Care Med 2006;32:1722e32.
[26] Cheatham ML. Abdominal compartment syndrome. Curr Opin Crit Care
2009;15:154e62.
[27] Grossman LC, Michalakis KG, Browne H, Payson MD, Segars JH. The
pathophysiology of ovarian hyperstimulation syndrome: an unrecognized
compartment syndrome. Fertil Steril 2010;94:1392e8.
[28] Cil T, Tummon IS, House AA, Taylor B, Hooker G, Franklin J, et al. A
tale of two syndromes: ovarian hyperstimulation and abdominal
compartment. Hum Reprod 2000;15:1058e60.
[29] Maslovitz S, Jaffa A, Eytan O, Wolman I, Many A, Lessing JB, et al.
Renal blood flow alteration after paracentesis in women with ovarian
hyperstimulation. Obstet Gynecol 2004;104:321e6.
[30] Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian
hyperstimulation syndrome: an update review. Obstet Gynecol Surv
1989;44:430e40.
[31] Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in
novel reproductive technologies: prevention and treatment. Fertil Steril
1992;58:249e61.
[32] Golan A, Weissman A. A modern classification of OHSS. Reprod
Biomed Online 2009;19:28e32.
[33] Practice Committee of American Society for Reproductive Medicine.
Ovarian hyperstimulation syndrome. Fertil Steril 2003;80:1309e14.
[34] Practice Committee of American Society for Reproductive Medicine.
Ovarian hyperstimulation syndrome. Fertil Steril 2008;90:S188e93.
[35] Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction
between early and late ovarian hyperstimulation syndrome. Fertil Steril
2000;73:901e7.
[36] Lee KH, Kim SH, Jee BC, Kim YJ, Suh CS, Kim KC, et al. Comparison
of clinical characteristics between early and late patterns in hospitalized
patients with ovarian hyperstimulation syndrome. Fertil Steril 2010;93:
2274e80.
[37] Chen CD, Chao KH, Yang JH, Chen SU, Ho HN, Yang YS. Comparison
of coasting and intravenous albumin in the prevention of ovarian
hyperstimulation syndrome. Fertil Steril 2003;80:86e90.
[38] Chen CD, Wu MY, Yang JH, Chen SU, Ho HN, Yang YS. Intravenous
albumin does not prevent the development of severe ovarian hyper-
stimulation syndrome. Fertil Steril 1997;68:287e91.
[39] Whelan 3rd JG, Vlahos NF. The ovarian hyperstimulation syndrome.
Fertil Steril 2000;73:883e96.
[40] Cheatham M, Malbrain M, Kirkpatrick A, Sugrue M, Parr M,
De Waele J, et al. Results from the international conference of experts on
intra-abdominal hypertension and abdominal compartment syndrome. II.
Recommendations. Intensive Care Med 2007;33:951e62.
[41] Cheatham M. Nonoperative management of intraabdominal hypertension
and abdominal compartment syndrome. World J Surg 2009;33:1116e22.
[42] Royal College of Obstetricians and Gynaecologists (RCOG). The
management of ovarian hyperstimulation syndrome. London (UK):
RCOG; 2006. pp. 11. (Green-top guideline; no. 5).[43] Shrivastav P, Nadkarni P, Craft I. Day care management of severe ovarian
hyperstimulation syndrome avoids hospitalization and morbidity. Hum
Reprod 1994;9:812e4.
[44] Lincoln SR, Opsahl MS, Blauer KL, Black SH, Schulman JD. Aggressive
outpatient treatment of ovarian hyperstimulation syndrome with ascites
using transvaginal culdocentesis and intravenous albumin minimizes
hospitalization. J Assist Reprod Genet 2002;19:159e63.
[45] Smith LP, Hacker MR, Alper MM. Patients with severe ovarian hyper-
stimulation syndrome can be managed safely with aggressive outpatient
transvaginal paracentesis. Fertil Steril 2009;92:1953e9.
[46] Fluker MR, Copeland JE, Yuzpe AA. An ounce of prevention: outpatient
management of the ovarian hyperstimulation syndrome. Fertil Steril
2000;73:821e4.
[47] Csokmay JM, Yauger BJ, Henne MB, Armstrong AY, Queenan JT,
Segars JH. Cost analysis model of outpatient management of ovarian
hyperstimulation syndrome with paracentesis: “Tap early and often”
versus hospitalization. Fertil Steril 2010;93:167e73.
[48] Victorino GP, Newton CR, Curran B. Effect of hypertonic saline on
microvascular permeability in the activated endothelium. J Surg Res
2003;112:79e83.
[49] Strandvik GF. Hypertonic saline in critical care: a review of the literature
and guidelines for use in hypotensive states and raised intracranial
pressure. Anaesthesia 2009;64:990e1003.
[50] Tan TS, Tan KH, Ng HP, Loh MW. The effects of hypertonic saline
solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment
using thromboelastography. Anaesthesia 2002;57:644e8.
[51] Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hypo-
natremia and its relation to brain damage. A prospective study. N Engl J
Med 1987;317:1190e5.
[52] Hew-Butler T, Almond C, Ayus JC, Dugas J, Meeuwisse W, Noakes T,
et al. Consensus statement of the 1st International Exercise-Associated
Hyponatremia Consensus Development Conference, Cape Town, South
Africa 2005. Clin J Sport Med 2005;15:208e13.
[53] Kolsen-Petersen JA, Nielsen JO, Tonnesen E. Acid base and electrolyte
changes after hypertonic saline (7.5%) infusion: a randomized controlled
clinical trial. Scand J Clin Lab Invest 2005;65:13e22.
[54] Oda JMD, Ueyama MMD, Yamashita KMD, Inoue TMD, Noborio MMD,
Ode YMD, et al. Hypertonic lactated saline resuscitation reduces the risk
of abdominal compartment syndrome in severely burned patients. J
Trauma 2006;60:64e71.
[55] Chen CD, Yang JH, Chao KH, Chen SU, Ho HN, Yang YS. Effects of
repeated abdominal paracentesis on uterine and intraovarian haemody-
namics and pregnancy outcome in severe ovarian hyperstimulation
syndrome. Hum Reprod 1998;13:2077e81.
[56] Ozgun MT, Batukan C, Oner G, Uludag S, Aygen EM, Sahin Y. Removal
of ascites up to 7.5 liters on one occasion and 45 liters in total may be
safe in patients with severe ovarian hyperstimulation syndrome. Gynecol
Endocrinol 2008;24:656e8.
[57] Cabrera J, Falcon L, Gorriz E, Pardo MD, Granados R, Quinones A, et al.
Abdominal decompression plays a major role in early postparacentesis
haemodynamic changes in cirrhotic patients with tense ascites. Gut 2001;
48:384e9.
[58] Al-Ramahi M, Leader A, Claman P, Spence J. A novel approach to the
treatment of ascites associated with ovarian hyperstimulation syndrome.
Hum Reprod 1997;12:2614e6.
[59] Abuzeid MI, Nassar Z, Massaad Z, Weiss M, Ashraf M, Fakih M. Pigtail
catheter for the treatment of ascites associated with ovarian hyperstim-
ulation syndrome. Hum Reprod 2003;18:370e3.
[60] Nelson SM. Prophylaxis of VTE in womendduring assisted reproduc-
tive techniques. Thromb Res 2009;123:S8e15.
[61] Ou YC, Kao YL, Lai SL, Kung FT, Huang FJ, Chang SY, et al.
Thromboembolism after ovarian stimulation: successful management of
a woman with superior sagittal sinus thrombosis after IVF and embryo
transfer: case report. Hum Reprod 2003;18:2375e81.
[62] Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine
treatment for severe ovarian hyperstimulation syndrome. Hum Reprod
1992;7:180e3.
10 C.-D. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 50 (2011) 2e10[63] Tsunoda T, Shibahara H, Hirano Y, Suzuki T, Fujiwara H,
Takamizawa S, et al. Treatment for ovarian hyperstimulation syndrome
using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol
2003;17:281e6.
[64] Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The
neurotransmitter dopamine inhibits angiogenesis induced by vascular
permeability factor/vascular endothelial growth factor. Nat Med 2001;7:
569e74.
[65] Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E,
Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist
administration blocks vascular endothelial growth factor (VEGF)-medi-
ated vascular hyperpermeability without altering VEGF receptor 2-
dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
Endocrinology 2006;147:5400e11.
[66] Alvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R,
Fernandez-Sanchez M, et al. Dopamine agonist cabergoline reduces
hemoconcentration and ascites in hyperstimulated women undergoing
assisted reproduction. J Clin Endocrinol Metab 2007;92:2931e7.
[67] Alvarez C, Alonso-Muriel I, Garcia G, Crespo J, Bellver J, Simon C,
et al. Implantation is apparently unaffected by the dopamine agonist
cabergoline when administered to prevent ovarian hyperstimulation
syndrome in women undergoing assisted reproduction treatment: a pilot
study. Hum Reprod 2007;22:3210e4.
[68] Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L,
Salgueiro PT, et al. Cabergoline reduces the early onset of ovarian
hyperstimulation syndrome: a prospective randomized study. Reprod
Biomed Online 2008;17:751e5.
[69] Youssef MAFM, van Wely M, Hassan MA, Al-Inany HG, Mochtar M,
Khattab S, et al. Can dopamine agonists reduce the incidence and
severity of OHSS in IVF/ICSI treatment cycles? A systematic review and
meta-analysis. Hum Reprod Update 2010;16:459e66.
[70] Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-
agonist treatment in Parkinson’s disease. Lancet Neurol 2007;6:
826e9.[71] Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular
heart disease and the use of dopamine agonists for Parkinson’s disease. N
Engl J Med 2007;356:39e46.
[72] Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, Landeras J,
Ballesteros A, Munoz E, et al. The non-ergot derived dopamine agonist
quinagolide in prevention of early ovarian hyperstimulation syndrome in
IVF patients: a randomized, double-blind, placebo-controlled trial. Hum
Reprod 2010;25:995e1004.
[73] Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K,
Griesinger G. Among patients treated for IVF with gonadotrophins and
GnRH analogues, is the probability of live birth dependent on the type of
analogue used? A systematic review and meta-analysis. Hum Reprod
Update 2006;12:651e71.
[74] Friden BE, Nilsson L. Gonadotrophin-releasing hormone-antagonist
luteolysis during the preceding mid-luteal phase is a feasible protocol in
ovarian hyperstimulation before in vitro fertilization. Acta Obstet
Gynecol Scand 2005;84:812e6.
[75] Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT,
Kolibianakis EM. Management of severe early ovarian hyperstimulation
syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online
2007;15:408e12.
[76] Rollene NL, Amols MH, Hudson SBA, Coddington CC. Treatment of
ovarian hyperstimulation syndrome using a dopamine agonist and
gonadotropin releasing hormone antagonist: a case series. Fertil Steril
2009;92:1169.e15e7.
[77] Moses MA, Harper J, Folkman J. Doxycycline treatment for lym-
phangioleiomyomatosis with urinary monitoring for MMPs. N Engl J
Med 2006;354:2621e2.
[78] Fainaru O, Adini I, Benny O, Bazinet L, Pravda E, D’Amato R, et al.
Doxycycline induces membrane expression of VE-cadherin on endothelial
cells and prevents vascular hyperpermeability. FASEB J 2008;22:3728e35.
[79] Fainaru O, Hornstein MD, Folkman J. Doxycycline inhibits vascular
leakage and prevents ovarian hyperstimulation syndrome in a murine
model. Fertil Steril 2009;92:1701e5.
